• STAAR Surgical (NasdaqGM:STAA) released a global market report on 12 September 2026 on vision correction procedure trends.
• The study highlights a structural shift in multiple regions away from laser eye surgery toward implantable lens correction using phakic ICLs.
• STAAR Surgical reports that surgeons and patients show growing interest in reversible procedures that are presented as carrying safety advantages.
• This fresh data on a move from laser to implantable lens correction should not be the only thing you weigh today. Check out 1 warning sign that STAAR Surgical investors should know about.

For a wider view on how changing vision technologies and medical data tools intersect, explore the broader set of healthcare AI opportunities via 39 healthcare AI stocks.

STAAR Surgical, a US-based medical equipment group with a market cap of about $1.2b, focuses on designing and manufacturing phakic implantable lenses and delivery systems, so a global pivot toward ICLs directly touches its core product line rather than a side offering.

Does the team leading STAAR Surgical have what it takes? See our full breakdown of the management team's track record and compensation.

What STAAR Surgical’s lens shift and leadership moves really signal

For STAAR Surgical, this market report does more than talk up ICL demand. It leans into the existing bull case that lens based correction can keep taking share from laser procedures, which is exactly the long term adoption story analysts are using in the Narrative. Pair that with David Bailey returning as Chief Commercial Officer and a new CTO, Ben Park, and you get a clearer message. Management is trying to line up commercial experience and product development around the same phakic ICL theme, while the known bear arguments around China exposure, single distributor risk, and cost controls remain firmly in place.

See how these catalysts shape STAAR Surgical's path to a $29.67 fair value.

The near term proof point is execution rather than theory. Watch how refractive procedure volumes, sell through, and inventory in China look in STAAR Surgical’s next couple of quarterly reports, especially as EVO+ rolls through that market and Bailey’s commercial plans start to show up in regional revenue and mix.

STAAR Surgical’s earnings story has a detail many shareholders skip

Headline results only tell part of the STAAR Surgical story, and internal checks flag something in how those profits are built that most holders never review closely. See what our checks flag about the quality of STAAR Surgical's earnings.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.